# **WEST Search History**

DATE: Tuesday, January 21, 2003

·		<b>Hit Count</b>	Set Name
Set Name side by side			result set
-	SPT,DWPI; PLUR=YES; OP=ADJ		
L1	matzuk-M\$.in. or Wang-p\$.in.	1289	L1
L2	L1 and nucleoplasmin	0	L2
L3	L1 and O1-236 gene	0	L3
L3 L4	11 and (oocyte or ovaries)	8	L4
L5	11 and ovary specific gene	0	L5
	nucleoplasmin	71	L6
L6	L6 and ovary specific gene	0	L7
L7		12	L8
L8	L6 and oocyte		
DB=U	SPT,PGPB,EPAB,DWPI; PLUR=YES; OP=ADJ	1	L9
L9	O1-236 gene	1	
L10	nucleoplasmin 2	2	L10
DB=U	SPT,DWPI; PLUR=YES; OP=ADJ		
L11	5563059.pn. or 5547854.pn. or 5661126.pn. or 5801016.pr	ı. 8	R L11
L12	ovary-specific genes and proteins O1-180	C	) L12
	WPI; PLUR=YES; OP=ADJ		
L13	ovary specific genes	1	L13
L14	113 and o1-180	(	) L14
_ <del>_</del>			

END OF SEARCH HISTORY

### => d his

(FILE 'HOME' ENTERED AT 15:55:12 ON 21 JAN 2003)

FILE 'MEDLINE, BIOTECHDS, EMBASE, BIOSIS, SCISEARCH, CANCERLIT, CAPLUS' ENTERED AT 15:55:23 ON 21 JAN 2003 786 S MATZUK-M?/AU L1786 S MATZUK M?/AU L217897 S WANG P?/AU L31 S (L1 OR L2) AND (OVAR? SPECIFIC GENE#) L436 S OVARY-SPECIFIC GENE# L50 S NUCLEOPLASMIN 2 L6 45 S NMP2 L7 13 S NPM2 L81 S L5 AND L8 L9 20 DUP REM L5 (16 DUPLICATES REMOVED) L10

=>

```
132:330621
    Ovary-specific genes and proteins 01-180,
TI
     O1-184 and O1-236/Npm2 of mouse and therapeutic uses
     Matzuk, Martin M.; Wang, Pei
IN
     Baylor College of Medicine, USA
PA
     PCT Int. Appl., 54 pp.
SO
     CODEN: PIXXD2
     Patent
DT
     English
LΑ
     ICM C07H021-02
IC
     3-3 (Biochemical Genetics)
CC
     Section cross-reference(s): 1, 6, 13
FAN.CNT 2
                                            APPLICATION NO.
                                                             DATE
                            DATE
                      KIND
     PATENT NO.
                                            WO 1999-US25209
                                                             19991028
                            20000504
                       A1
     WO 2000024755
PΙ
         W: AU, CA, JP, US
         RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL,
             PT, SE
                                            EP 1999-956718
                                                             19991028
                             20010822
                        A1
     EP 1124840
         R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
              IE, FI
                                                             20010427
                                            US 2001-844864
                             20020411
                        A1
     US 2002042926
                             19981028
PRAI US 1998-106020P
                        P
                             19991028
     WO 1999-US25209
     Ovary-specific proteins 01-180, 01-184 and 01-236 from mouse,
     polynucleotides encoding them, antibodies which are immunoreactive with
AB
      them and vectors and host cells contg. 01-180, 01-184 or 01-236 are
      provided. 01-236 protein is homologous to Xenopos nucleoplasmin (Npm2).
      Both O1-236/Npm2 and Xnpm2 genes have similar expression patterns in
      oocytes. Structure and localization of the mouse gene Npm2 on chromosome
      14 between D14Mit203 and D14Mit32 was detd. Methods for detecting cell
      proliferative or degenerative disorders of ovarian origin which are
      assocd. with O1-180, O1-184 or O1-236 are provided. Further provided are
      methods for the evaluation of potential contraceptives using the proteins
      of the invention, as well as methods for the screening for genetic
      mutations in signaling pathways that are assocd. with some forms of human
      infertility or gynecol. cancers, also using the proteins/mRNAs/genes of
      the invention.
      mouse gene Npm2 nucleoplasmin sequence mapping; cDNA sequence ovary
 ST
      specific protein mouse
      Genetic markers
 IT
          (D14Mit203 and D14Mit32, Npm2 gene mapped between; ovary-
         specific genes and proteins 01-180, 01-184 and
         O1-236/Npm2 of mouse and therapeutic uses)
      Gene, animal
      RL: BOC (Biological occurrence); BSU (Biological study, unclassified);
 IT
 PRP
       (Properties); THU (Therapeutic use); BIOL (Biological study); OCCU
       (Occurrence); USES (Uses)
          (Npm2; ovary-specific genes and proteins
          O1-180, O1-184 and O1-236/Npm2 of mouse and therapeutic uses)
       Eukaryote (Eukaryotae)
  IT
       Prokaryote
          (cell, as expression host; ovary-specific
          genes and proteins 01-180, 01-184 and 01-236/Npm2 of mouse and
          therapeutic uses)
       Mutation
  IT
          (detn. of mutations in diseases; ovary-specific
          genes and proteins O1-180, O1-184 and O1-236/Npm2 of mouse and
```

## **WEST Search History**

DATE: Tuesday, January 21, 2003

Set Name side by side	Query	Hit Count	Set Name result set		
DB=USPT,DWPI; PLUR=YES; OP=ADJ					
L1	matzuk-M\$.in. or Wang-p\$.in.	1289	L1		
L2	L1 and nucleoplasmin	0	L2		
L3	L1 and O1-236 gene	0	L3		
L4	11 and (oocyte or ovaries)	8	L4		
L5	11 and ovary specific gene	0	L5		
L6	nucleoplasmin	71	L6		
L7	L6 and ovary specific gene	0	L7		
L8	L6 and oocyte	12	L8		
$DB=USPT,PGPB,EPAB,DWPI;\ PLUR=YES;\ OP=ADJ$					
L9	O1-236 gene	1	L9		
L10	nucleoplasmin 2	2	L10		

END OF SEARCH HISTORY

**Generate Collection** Print

L8: Entry 6 of 12

File: USPT

Feb 13, 2001

DOCUMENT-IDENTIFIER: US 6187749 B1

TITLE: Methods for variation of chromatin condensation

Brief Summary Text (8):

A further technique which is applicable in certain circumstances is known as premature chromosome condensation (PCC). It was first described by Hittelman and Rao, (1978) Cancer Res. 38:416-423. This technique results in the condensation of chromatin/chromasomes in interphase cells. It may be achieved in vitro using CHO or HeLa cells, or inactivated Sendai virus. Alternatively non-physiological agents such as polyethylene glycol (PEG) may be involved as well as synthetic acidic proteins such as poly L-glutamic acid and extracts from non-mammalian cells such as Xenopus egg extracts from germ-line cells such as hamster oocytes. The technique has been utilised many times in the art, for example in studies of acute lymphblastic leukaemia (Macleod et al., Genes, Chromosomes & Cancer, (1989) 1, 135-138). It is however a very difficult technique to apply in the laboratory and only a limited number of research groups utilise it.

Brief Summary Text (10):

A number of in vitro systems, which mimic the events at fertilisation, have been developed in order to enable the changes in chromatin structure and the mechanisms of chromatin remodelling to be studied. These are reviewed by Leno et al., in John Innes Review, The Chromosome, Ed. J S Heslop-Harrison, (1992) R. B Flavell Bros. Scientific Publishers. p135-147. The principal component found to be effective in the decondensation and remodelling of sperm is nucleoplasmin, a protein isolated from the eggs of Xenopus laevis.

**Print Generate Collection** 

L8: Entry 4 of 12

File: USPT

May 15, 2001

DOCUMENT-IDENTIFIER: US 6232107 B1

TITLE: Luciferases, fluorescent proteins, nucleic acids encoding the luciferases and fluorescent proteins and the use thereof in diagnostics, high throughput screening and novelty items

Detailed Description Text (355):

Exemplary cells include bacteria (e.g., E. coli), plant cells, cells of mammalian origin (e.g., COS cells, mouse L cells, Chinese hamster ovary (CHO) cells, human embryonic kidney (HEK) cells, African green monkey cells and other such cells known to those of skill in the art), amphibian cells (e.g., Xenopus laevis oocytes), yeast cells (e.g., Saccharomyces cerevisiae, Pichia pastoris), and the like. Exemplary cells for expressing injected RNA transcripts include Xenopus laevis oocytes. Eukaryotic cells that are preferred for transfection of DNA are known to those of skill in the art or may be empirically identified, and include HEK293 (which are available from ATCC under accession #CRL 1573); Ltk.sup.- cells (which are available from ATCC under accession #CCL1.3); COS-7 cells (which are available from ATCC under accession #CRL 1651); and DG44 cells (dhfr.sup.- CHO cells; see, e.g., Urlaub et al. (1986) Cell. Molec. Genet. 12: 555). Presently preferred cells include strains of bacteria and yeast.

Detailed Description Text (363):

Exemplary cells include bacteria (e.g., E. coli), plant cells, cells of mammalian origin (e.g., COS cells, mouse L cells, Chinese hamster ovary (CHO) cells, human embryonic kidney (HEK) cells, African green monkey cells and other such cells known to those of skill in the art), amphibian cells (e.g., Xenopus laevis oocytes), yeast cells (e.g., Saccharomyces cerevisiae, Pichia pastoris), and the like. Exemplary cells for expressing injected RNA transcripts include Xenopus laevis oocytes. Eukaryotic cells that are preferred for transfection of DNA are known to those of skill in the art or may be empirically identified, and include HEK293 (which are available from ATCC under accession #CRL 1573); Ltk.sup.- cells (which are available from ATCC under accession #CCL1.3); COS-7 cells (which are available from ATCC under accession #CRL 1651); and DG44 cells (dhfr.sup.- CHO cells; see, e.g., Urlaub et al. (1986) Cell. Molec. Genet. 12: 555). Presently preferred cells include strains of bacteria and yeast.

Other Reference Publication (68):

Badminton et al., nucleoplasmin-targeted aequorin provides evidence for a nuclear calcium barrier, Expt. Cell Research 216(1): 236-243 (1995).

**Print Generate Collection** 

L8: Entry 3 of 12

File: USPT

Jun 12, 2001

DOCUMENT-IDENTIFIER: US 6245567 B1

TITLE: Activating egg extracts and method of preparation

Brief Summary Text (4):

Jackson, Seminars in Perinatology 15:49 (1991), describes various procedures for prenatal diagnosis, including procedures to diagnose diseases. These procedures involve analysis of the DNA present in early embryonic stages. Specifically, Jackson mentions the use of a polymerase chain reaction to amplify genes, and the possibility of testing oocytes by polar body assay. According to Jackson:

Detailed Description Text (33):

Freshly ovulated Xenopus eggs can be hardened by stabilizing the eggs vitelline envelope as described by Wangh, J. Cell Science 93:1 (1989). Obtaining freshly ovulated eggs from female Xenopus is facilitated by injecting hormones which cause Xenopus to ovulate. Injecting 600 units of human chorionic gonadotropin (HCG) into a Xenopus female generally brings about ovulation within 12-15 hours. Injection of pregnant mare serum gonadotropin about 24 hours before HCG treatment significantly increases the yield of mature eggs. Furthermore, repeated ovulation of frogs once every 4-8 months improves the yield of eggs by increasing the synchrony of oocyte development in the ovary.

Other Reference Publication (14):

Masui, "Hormonal And Cytoplasmic Control of The Maturation of Frog Oocytes," Ontogenez vol. 3 No. 6 pp. 574-587 (1972).

Other Reference Publication (15):

Masui et al., "Roles of Ca Ions And Ooplasmic Factors In The Resumption of Metaphase-Arrested Meiosis In Rana Pipiens Oocytes, "Symp. Soc. Exp. Biol. 38:45-66 (1984).

Other Reference Publication (36):

Cox et al., "Extracts From Eggs And Oocytes of Xenopus Laevis Differ In Their Capacities For Nuclear Assembly And DNA Replication, " J. Cell Science 97:177-184 (1990).

Other Reference Publication (55):

Philpott et al., "Sperm Decondensation In Xenopus Egg Cytoplasm Is Mediated By Nucleoplasmin, " Cell 65:569-578 (1991).

Other Reference Publication (56):

Philpott et al., "Nucleoplasmin Remodels Sperm Chromatin In Xenopus Egg Extracts," Cell 69:759-767 (1992).

Other Reference Publication (58):

Sleeman et al., "Patterns of DNA Replication In Drosophilia Polytene Nuclei Replicating In Xenopus Egg And Oocyte Extracts," J. Cell Science 101:509-515 (1992).